Oncology Research Program

Full access

Highlights of the NCCN Oncology Research Program

The NCCN Oncology Research Program (ORP) strives to improve the quality of life for patients and reduce cancer-related deaths by advancing cancer therapies through research. Since the program's establishment in 1999, the NCCN ORP has brought millions of dollars in research grants to investigators at NCCN Member Institutions. Research grants are provided to NCCN through collaborations with pharmaceutical and biotechnology companies; these grants are in turn used to support scientifically meritorious cancer research efforts.

NCCN ORP studies typically explore new avenues of clinical investigation and seek answers to important cancer-related questions. All studies are approved and funded through a scientific peer-review process and are overseen by the ORP.

An NCCN study funded through the grant mechanism is highlighted below.

The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Principal Investigator: Mario Pineda, MD, PhD

Condition: Recurrent epithelial ovarian cancer, recurrent fallopian tube cancer, and recurrent primary peritoneal cancer

Institution: Robert H. Lurie Comprehensive Cancer Center of Northwestern University

This is a single-arm phase II trial. All patients will receive 1.5 mg orally of tivozanib given daily for 3 weeks with 1 week off to complete a 4-week cycle. At the start of each cycle, patients will see a clinician, who will obtain a pertinent history, perform a physical examination, draw serum CA-125 values, and determine whether the patient is appropriate for therapy. Treatment will continue until documented disease progression or the patient is unable to tolerate further therapy because of excessive toxicity. Statistical analyses will focus on estimation of overall response rates in patients with platinum-resistant ovarian cancer, as stated in the primary objective. For the secondary objective, the Kaplan-Meier method will be used to estimate the median and overall distribution of progression-free survival. Toxicity will also be evaluated as a secondary objective and grades will be summarized by counts and frequencies.

Primary Objective:

  • Determine the clinical activity of tivozanib in patients with platinum-resistant, recurrent ovarian, fallopian tube, or primary peritoneal cancer. These disease entities will be referred to collectively as ovarian cancer

Secondary Objective:

  • Determine the potential survival advantage and characterize the safety of single-agent tivozanib in patients with platinum-resistant ovarian cancer

Contacts: Mario Pineda, MD, PhD • 312-472-4684

Rachel Bers, BS • 312-472-5726 • r-bers@northwestern.edu

Doreine Carson, MS • 312 472-4681 • d-carson@northwestern.edu

ClinicalTrials.gov Identifier: NCT01853644

The goal of the Highlights of the NCCN Oncology Research Program (ORP) is to provide readers with more information on the ORP, including studies currently accruing patients.

For more information on specific trials, including patient selection criteria, please use the contact information listed with each study.

For more information on the NCCN ORP, including a complete detailing of the clinical studies currently underway at NCCN Member Institutions, please access the NCCN ORP pages at NCCN.org/clinical_trials/clinicians.asp.

  • Collapse
  • Expand
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 273 54 2
PDF Downloads 16 6 1
EPUB Downloads 0 0 0